1. ALKS 8700
Alkremes Inc. is developing a novel formulation called ALKS 8700 to treat demyelinating neurodegenerative disorders of the central nervous system such as multiple sclerosis (MS).
Ankar Pharmaceuticals, a Spanish-Filipino start-up in biopharmaceuticals, has been working on the development of their premier drug candidate for treating multiple sclerosis (MS), called AP-1. The unique property of this pipeline drug is its ability to excel in terms of prophylactic measures in people suspected to be affected by the condition, as well as in those with a full-blown case history of MS and relapses. This gives the oral formulation an advantageous edge over many contemporary drugs, fingolimod being the latest to be approved, for treating MS.